| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 3 securities · passive | ||||||
|
Latigo Biotherapeutics, Inc.
13G
LTGO · 517954103
|
19.9% |
10/29/2026
Event 9/30/2026
|
||||
| Westlake BioPartners Fund I, L.P. | 9.0% | |||||
| Westlake BioPartners GP I, LLC | 9.0% | |||||
| Westlake BioPartners Fund II, L.P. | 7.8% | |||||
| Westlake BioPartners GP II, LLC | 7.8% | |||||
| Westlake BioPartners Opportunity Fund I, L.P. | 3.2% | |||||
| Westlake BioPartners Opportunity GP I, LLC | 3.2% | |||||
| Dr. Beth C. Seidenberg | 19.9% | |||||
|
Electra Therapeutics, Inc.
13G
ETRA · 284825106
|
10.1% |
10/29/2026
Event 9/30/2026
|
||||
| Westlake BioPartners Fund I, L.P. | 5.6% | |||||
| Westlake BioPartners GP I, LLC | 5.6% | |||||
| Westlake BioPartners Fund II, L.P. | 4.5% | |||||
| Westlake BioPartners GP II, LLC | 4.5% | |||||
| Dr. Beth C. Seidenberg | 10.1% | |||||
|
Kyverna Therapeutics, Inc.
13G/A
KYTX · 501976104
|
7.8% |
2/6/2026
Event 12/31/2025
|
||||
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.3% | |||||
| Westlake BioPartners GP I, LLC ("Westlake GP I") | 6.3% | |||||
| Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") | 1.5% | |||||
| Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") | 1.5% | |||||
| Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.